559
views
0
recommends
+1 Recommend
2 collections
    24
    shares

      Call for Papers: Sex and Gender in Neurodegenerative Diseases

      Submit here before September 30, 2024

      About Neurodegenerative Diseases: 3.0 Impact Factor I 4.3 CiteScore I 0.695 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Is Intra-Arterial Treatment for Acute Ischemic Stroke Less Effective in Women than in Men?

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Stroke etiology and outcome after ischemic stroke differ between men and women. We examined if sex modifies the effect of intra-arterial treatment (IAT) in a randomized clinical trial of IAT for acute ischemic stroke in the Netherlands (MR CLEAN).

          Patients and Methods

          The primary outcome was the score on the modified Rankin scale at 90 days. We tested for interaction between sex and treatment and estimated the treatment effect by sex with multiple ordinal logistic regression with adjustment for prognostic factors.

          Results

          All 500 patients were included in the analysis; 292 (58.4%) were men. The treatment effect (adjusted common odds ratio) was 2.39 [95% confidence interval (CI) 1.55-3.68] in men and 0.99 (95% CI 0.60-1.66) in women (p interaction = 0.016). In women, mortality was higher in the intervention group than in the control group (24 vs. 15%, p = 0.07). Serious adverse events occurred more often in women than in men undergoing intervention. There were no differences in neuro-imaging outcomes.

          Discussion and Conclusion

          Contrary to other studies, we found a significant interaction between sex and treatment effect in the MR CLEAN trial. Pooled analyses of all published thrombectomy trials did not confirm this finding. In MR CLEAN, women seem to have a slightly more unfavorable profile, causing higher mortality and more serious adverse events, but insufficient to explain the absence of an overall effect. This suggests a play of chance and makes it clear that IAT should not be withheld in women.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial

          Background Endovascular or intra-arterial treatment (IAT) increases the likelihood of recanalization in patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion. However, a beneficial effect of IAT on functional recovery in patients with acute ischemic stroke remains unproven. The aim of this study is to assess the effect of IAT on functional outcome in patients with acute ischemic stroke. Additionally, we aim to assess the safety of IAT, and the effect on recanalization of different mechanical treatment modalities. Methods/design A multicenter randomized clinical trial with blinded outcome assessment. The active comparison is IAT versus no IAT. IAT may consist of intra-arterial thrombolysis with alteplase or urokinase, mechanical treatment or both. Mechanical treatment refers to retraction, aspiration, sonolysis, or use of a retrievable stent (stent-retriever). Patients with a relevant intracranial proximal arterial occlusion of the anterior circulation, who can be treated within 6 hours after stroke onset, are eligible. Treatment effect will be estimated with ordinal logistic regression (shift analysis); 500 patients will be included in the trial for a power of 80% to detect a shift leading to a decrease in dependency in 10% of treated patients. The primary outcome is the score on the modified Rankin scale at 90 days. Secondary outcomes are the National Institutes of Health stroke scale score at 24 hours, vessel patency at 24 hours, infarct size on day 5, and the occurrence of major bleeding during the first 5 days. Discussion If IAT leads to a 10% absolute reduction in poor outcome after stroke, careful implementation of the intervention could save approximately 1% of all new stroke cases from death or disability annually. Trial registration NTR1804 (7 May 2009)/ISRCTN10888758 (24 July 2012). Electronic supplementary material The online version of this article (doi:10.1186/1745-6215-15-343) contains supplementary material, which is available to authorized users.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Sex differences and stroke prevention.

            (2014)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prevention and management of stroke in women.

              Stroke is the leading cause of acquired disability and the third leading cause of death in women worldwide. Sex differences in risk factors, treatment response and quality of life after stroke complicate stroke management in women. Women have an increased lifetime incidence of stroke compared to men, largely due to a sharp increase in stroke risk in older postmenopausal women. Women also have an increased lifetime prevalence of stroke risk factors, including hypertension and atrial fibrillation in postmenopausal women, as well as abdominal obesity and metabolic syndrome in middle-aged women. Controversy continues over the risks of oral contraceptives, hormone therapy and surgical intervention for carotid stenosis in women. Pregnancy and the postpartum period represent a time of increased risk, presenting challenges to stroke management. Recognition of these issues is critical to improving acute care and functional recovery after stroke in women.
                Bookmark

                Author and article information

                Journal
                Interv Neurol
                Interv Neurol
                INE
                Interventional Neurology
                S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch )
                1664-9737
                1664-5545
                September 2016
                1 July 2016
                1 July 2016
                : 5
                : 3-4
                : 174-178
                Affiliations
                [1] aErasmus MC University Medical Center, Rotterdam, The Netherlands
                [2] bMaastricht University Medical Center, Maastricht, The Netherlands
                [3] cAcademic Medical Center, Amsterdam, The Netherlands
                [4] dLeiden University Medical Center, Leiden, The Netherlands
                Author notes
                *Inger de Ridder, Erasmus MC University Medical Center, Department of Neurology Room Ee2240, PO Box 2040 NL-3000 CA Rotterdam (The Netherlands) E-Mail i.deridder@ 123456erasmusmc.nl

                I.R.d.R. and P.S.S.F. contributed equally to this work. The MR CLEAN trial is registered under No. NTR1804 in the Dutch trial register and under ISRCTN10888758 in the ISRCTN register.

                Article
                PMC5075805 PMC5075805 5075805 ine-0005-0174
                10.1159/000447331
                5075805
                27781046
                93a45f49-1561-4eac-86a9-c8a7e36e0d9a
                Copyright © 2016 by S. Karger AG, Basel
                History
                Page count
                Figures: 1, Tables: 2, References: 13, Pages: 5
                Categories
                Original Paper

                Cerebral infarction,Endovascular treatment,Sex,Outcome
                Cerebral infarction, Endovascular treatment, Sex, Outcome

                Comments

                Comment on this article